Allspring Global Investments Holdings LLC Acquires 84,926 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Allspring Global Investments Holdings LLC increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 16,717.7% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 85,434 shares of the biotechnology company’s stock after buying an additional 84,926 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.09% of Sarepta Therapeutics worth $10,602,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SRPT. Blue Trust Inc. increased its holdings in Sarepta Therapeutics by 896.5% in the 3rd quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock worth $71,000 after buying an additional 511 shares in the last quarter. Bank Pictet & Cie Europe AG increased its holdings in Sarepta Therapeutics by 27.7% in the 3rd quarter. Bank Pictet & Cie Europe AG now owns 2,827 shares of the biotechnology company’s stock worth $353,000 after buying an additional 613 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Sarepta Therapeutics by 59,222.7% in the 3rd quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after buying an additional 75,805 shares in the last quarter. Values First Advisors Inc. bought a new stake in Sarepta Therapeutics in the 3rd quarter worth about $59,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Sarepta Therapeutics by 112.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock worth $747,000 after buying an additional 3,180 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $176.77.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $105.35 on Wednesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1 year low of $101.15 and a 1 year high of $173.25. The stock’s 50 day simple moving average is $118.57 and its two-hundred day simple moving average is $124.07. The company has a market cap of $10.06 billion, a price-to-earnings ratio of 84.28 and a beta of 0.75.

Insiders Place Their Bets

In other news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.